Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs

NCT01904682 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

45

Enrollment

INDUSTRY

Sponsor class

Conditions

Myelodysplastic Syndromes

Interventions

DRUG: Oral rigosertib

Sponsor

Traws Pharma, Inc.